Revolution Medicines (RVMD) Operating Expenses (2019 - 2026)

Revolution Medicines' Operating Expenses history runs 8 years deep, the most recent figure standing at $445.2 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 84.92% year-over-year to $445.2 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 75.68% YoY), while the FY2025 annual figure was $1.2 billion, up 71.48% from the prior year.
• Operating Expenses for Q1 2026 stood at $445.2 million, up from $361.6 million in the prior quarter.
• The five-year high for Operating Expenses was $445.2 million in Q1 2026, with the low at $65.5 million in Q1 2022.
• The 5-year median for Operating Expenses is $156.6 million (2024), against an average of $182.9 million.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses soared 134.6% in 2023, then increased 19.69% in 2024.
• Revolution Medicines' Operating Expenses stood at $77.0 million in 2022, then jumped by 134.6% to $180.7 million in 2023, then grew by 19.69% to $216.3 million in 2024, then soared by 67.18% to $361.6 million in 2025, then climbed by 23.12% to $445.2 million in 2026.
• Business Quant data shows RVMD's Operating Expenses at $445.2 million in Q1 2026, $361.6 million in Q4 2025, and $315.3 million in Q3 2025.